Aurigene Pharmaceutical Services is set to invest nearly $100 million investment to expand its CRDMO business, strengthening its role in the growing pharmaceutical outsourcing market.
The Bengaluru-based company plans to enhance its research and manufacturing capabilities to meet increasing global demand from pharmaceutical companies and biotechnology firms. As drugmakers look to reduce costs and speed up development timelines, many are turning to specialized partners like Aurigene for integrated research and manufacturing support.
Aurigene provides end-to-end services, helping companies move from early drug discovery to commercial manufacturing under a single platform. Its offerings cover small molecules, biologics, peptides and other advanced therapies, making it a preferred partner for global clients seeking efficient drug development solutions.
The planned investment will be used to expand infrastructure, upgrade laboratories and add advanced manufacturing technologies. These improvements are expected to increase capacity and support more complex contract manufacturing projects.
Also Read: Pfizer Extends Heart Drug Protection, Keeps Generics Away Till 2031
The global CRDMO market has seen strong growth in recent years, driven by rising demand for outsourced pharmaceutical services. Drug companies increasingly rely on external partners to manage research, clinical development and production, allowing them to focus on innovation and market expansion.
India has become an important hub for pharmaceutical manufacturing in India due to its skilled scientific workforce, cost advantages and improving regulatory standards. Companies operating in the country continue to attract international business by offering high-quality research and manufacturing capabilities at competitive costs.
Aurigene’s expansion reflects confidence in the long-term potential of the outsourcing sector. By investing in new facilities and technologies, the company aims to strengthen its position in the global pharmaceutical supply chain and win larger contracts from international clients.
The move also highlights the growing importance of biopharmaceutical services in the pharmaceutical industry. Companies that can offer research, development and manufacturing under one roof are becoming increasingly valuable to drugmakers looking for faster and more streamlined processes.
With this expansion, Aurigene is positioning itself to benefit from rising demand for global pharma outsourcing while reinforcing India’s role as a key player in global drug development and manufacturing.
.jpg)
.jpg)
